Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 14, 2000

View Archived Issues

Medarex and Oxford GlycoSciences to codevelop human antibody therapeutics

GlycoDesign and Seikagaku expand drug development agreement

Safety study of anti-hepatitis C ribozyme compound completed

Oxygent reduces the need for donor blood in phase III trial

Synthetic antioxidant compounds extend the life span of C. elegans

St. John's wort extract and imipramine equally efficacious in treating depression

Telomerase immunization induces antitumor response

Nebulized heparin reduces airways inflammation, improves spirometric parameters in asthma

German scientists study antisense oligonucleotides as a novel, noninvasive approach to asthma

Renal I/R injury prevented by VAS-971 therapy in canine model

HuM291 appears to induce transplant tolerance via apoptosis of activated T-cells

New leads in the search for next-generation microtubule-directed taxoids

Clinical candidate for allergic cutaneous disorders selected at Japan Energy

Cystistat approved for expanded indications in Europe

Analgesic activity demonstrated for Abbott's novel nAChR ligands

Vernalis patents new NMDA antagonists with favorable cortical to cerebellar ratio

Recent patent covers heterocyclic 5-HT reuptake inhibitors discovered at BMS

Potential new anticonvulsants presented by Boehringer Ingelheim

Screening collaboration between CDD and CST to identify novel kinase inhibitors

Clinical trials with polymer platinate AP-5280 to begin

Inhibitors of nitric oxide synthase in early development at Pharmacia

Exclusive access to technology for potential cancer vaccine granted to Viragen

Nanomolar binding affinity for A3 receptor demonstrated for certain new thiazolopyrimidines

British Biotech designs new LTA4 hydrolase inhibitors

Prodrugs of known BK(Ca) channel opener reported by BMS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...